DADimuthu Angage

Dimuthu Angage

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dimuthu Angage has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies

    by Isabelle G Henshall, Jill Chmielewski, Dimuthu Angage, Ornella Romeo, Keng Heng Lai, Kaitlin R Turland, Nicki Badii, Michael Foley, Robin F Anders, James G Beeson, et al.

    Malaria merozoite surface proteins (MSPs) are thought to have important roles in red blood cell (RBC) invasion and their exposure on the parasite surface makes them attractive vaccine candidates. However, their role in invasion has not been directly demonstrated and their biological functions remain unknown. One of the most abundant merozoite surface proteins is Pf MSP2, a likely ancestral protein that has been maintained in the Plasmodium falciparum lineage and is a focus of vaccine development. Using CRISPR-Cas9 gene editing, we removed Pf MSP2 from two different P. falciparum lines with no impact on parasite replication or phenotype in vitro, demonstrating that it is not essential for RBC invasion. Interestingly, loss of Pf MSP2 led to increased inhibitory potency of antibodies targeting other merozoite proteins involved in invasion, particularly Pf AMA1. In a solid-phase model, increasing concentrations of Pf MSP2 protein reduced binding of different antibodies against Pf AMA1 in a dose-dependent manner. These data suggest that Pf MSP2 can modulate the susceptibility of merozoites to protective inhibitory antibodies. The results of this study change our understanding of the potential functions of Pf MSP2 and establish a new concept in malaria where a surface protein can reduce the protective efficacy of antibodies targeting a different antigen. These findings have important implications for understanding malaria immunity and informing vaccine development.


  • Open Access

    Development of a novel therapy for systolic heart failure

    by Corey Pollock, Xilun Wang, Hussam Alsaraji, Joseph Menassa, George Mbogo, Dimuthu Angage, Benjamin Richards, Jason Glab, Keshava K Datta, Liana Theodoridis, et al.

    Heart failure presents a critical health challenge with a 5-year mortality rate of up to 50%. Conventional treatments often lead to bradycardia or hypotension due to their impact on patient hemodynamics. To address this issue, we utilized high-throughput drug screening combined with structure-activity relationship-based medicinal chemistry to develop a novel drug-like compound that effectively blocks the β-adrenergic receptor (β-AR) mediated apoptosis pathway. This compound demonstrated both safety and efficacy in pre-clinical mouse models without adversely affecting cardiac output. Through thermal proteome profiling mass spectrometry, we identified the compound’s target as Wdr3, a regulator of the Hippo signaling pathway. This target identification was further validated using CRISPR-based knockout experiments. Our findings provide a valuable framework for the development of hemodynamically neutral therapies aimed at treating systolic heart failure.

  • Open Access

    A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites

    by Dimuthu Angage, Jill Chmielewski, Janesha C. Maddumage, Eva Hesping, Sabrina Caiazzo, Keng Heng Lai, Lee Ming Yeoh, Joseph Menassa, D. Herbert Opi, Callum Cairns, et al.

    Apical membrane antigen-1 (AMA1) is a conserved malarial vaccine candidate essential for the formation of tight junctions with the rhoptry neck protein (RON) complex, enabling Plasmodium parasites to invade human erythrocytes, hepatocytes, and mosquito salivary glands. Despite its critical role, extensive surface polymorphisms in AMA1 have led to strain-specific protection, limiting the success of AMA1-based interventions beyond initial clinical trials. Here, we identify an i-body, a humanised single-domain antibody-like molecule that recognises a conserved pan-species conformational epitope in AMA1 with low nanomolar affinity and inhibits the binding of the RON2 ligand to AMA1. Structural characterisation indicates that the WD34 i-body epitope spans the centre of the conserved hydrophobic cleft in AMA1, where interacting residues are highly conserved among all Plasmodium species. Furthermore, we show that WD34 inhibits merozoite invasion of erythrocytes by multiple Plasmodium species and hepatocyte invasion by P. falciparum sporozoites. Despite a short half-life in mouse serum, we demonstrate that WD34 transiently suppressed P. berghei infections in female BALB/c mice. Our work describes the first pan-species AMA1 biologic with inhibitory activity against multiple life-cycle stages of Plasmodium. With improved pharmacokinetic characteristics, WD34 could be a potential immunotherapy against multiple species of Plasmodium.


  • Open Access

    A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites

    by Michael Foley, Dimuthu Angage, Robin Anders, Jill Chmielewski, Janesha Maddumage, Eva Hesping, Sabrina Caiazzo, Keng Heng Lai, Lee Yeoh, Herbert Opi, et al.

    Broadly cross-reactive anti-malarial vaccines and therapeutic interventions are needed to achieve better outcomes in controlling and, eventually, eradicating malaria. Apical membrane antigen-1 (AMA1) is a structurally and functionally conserved malarial vaccine candidate involved in the tight junction formation with the rhoptry neck protein (RON) complex at the host cell-parasite interface. This interaction is crucial for all Plasmodium parasites to invade human erythrocytes, hepatocytes and mosquito salivary glands effectively. However, extensive surface polymorphisms have induced P. falciparum strain-specific protection which has so far hindered the progression of AMA1-based interventions beyond the first clinical trial. Here, we identified a humanised single-domain (i-body) that recognises a conserved pan-species conformational epitope in AMA1 with low nanomolar affinity and inhibits the binding of the RON2 ligand to AMA1. Structural characterisation indicated that the WD34 i-body epitope engages the centre of the conserved hydrophobic cleft in AMA1, where interacting residues are highly conserved among all Plasmodium species and other apicomplexans. Further, we showed that WD34 inhibits merozoite invasion into RBCs by multiple Plasmodium species and hepatocyte invasion by P. falciparum sporozoites. Our work describes the identification of the first pan-species AMA1 biologic with high multi-lifecycle stage invasion inhibitory activity. This work identifies new tools for species-independent immunoprophylaxis and a possible target for structure-based vaccine development against malaria.